Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Urine Test Identifies Risk of Necrotizing Enterocolitis

By LabMedica International staff writers
Posted on 30 Apr 2013
In premature babies, abnormal gut bacteria can be found days before the onset of the devastating intestinal disease known as necrotizing enterocolitis (NEC).

Examination of stool samples from preterm infants by molecular techniques and urinary metabolomic analysis has revealed differences between those at risk of NEC and those who will not develop the disease.

Scientists at Cincinnati Children's Hospital (OH, USA) collaborating with other institutes, studied between October 2009 and August 2010, a total of 35 preterm infants of less than 29 weeks gestational age and whose weight was less than 1,200 grams at birth, The primary analysis included 11 infants who developed NEC and 21 control infants. The infant microbiome was analyzed by postnatal periods, 4 to 9 days and 10 to 16 days.

Bacterial DNA was extracted from infant stool samples using one of two methods: phenol-chloroform or the QiaAmp DNA stool kit (Qiagen Sciences; Germantown, MD, USA). The 16S ribosomal ribonucleic acid ( rRNA) gene was amplified and sequenced using 454 FLX Titanium sequencing (454 Life Sciences, Branford, CT, USA). Urine samples were analyzed by nuclear magnetic resonance.

Babies who later went on to develop NEC had a lower diversity of gut bacteria 4 to 9 days after birth, with increased level of Firmicutes or Enterobacteriaceae, but lacked the Propionibacterium found in healthy babies. All of the babies with NEC also had unusual levels of specific bacteria. Babies whose NEC started early, between 7 to 12 days after birth had abnormally high levels of Firmicutes, while babies whose NEC started later, 19 to 31 days, had high levels of Enterobacteriaceae. No difference was found in the relative abundance of Propionibacterium between NEC and control samples collected from days 10 to 16 of life.

No urinary metabolites differed significantly among all NEC cases and controls. However, three metabolites, alanine, pyridoxine (4-pyridoxate) and histidine, significantly distinguished NEC-I and NEC-II from each other as well as one of the NEC sub-types from controls.

Alanine was significantly higher in NEC-I versus NEC-II and NEC-I versus the control samples though the metabolite did not differ between all NEC versus control samples.

Ardythe L. Morrow, PhD, the senior author of the study said, "Our data show that onset of NEC appears to be related to having abnormally high levels of specific bacteria in the gut during the first week or two of life. Our data also indicate that a simple urine test looking at levels of alanine and histidine, which appear altered by these bacteria, can be used early in life to identify babies at risk of NEC." The study was published on April 16, 2013, in the journal Microbiome.

Related Links:

Cincinnati Children's Hospital
Qiagen Sciences
454 Life Sciences



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Piezoelectric Micropump
Disc Pump
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.